What caused the FSPM stock jump on Jan 24, 2026?

The move appears driven by very low liquidity and a small prior close, turning modest buy demand into a **9,900.00%** one-day rise. There was no major earnings or corporate press release tied to FusionPharm, Inc. during the move.

What is Meyka AI's view on FSPM stock?

Meyka AI rates FSPM **58.81 (C+) | HOLD** and projects a 1-year model target of **$0.00051**. The platform highlights high volatility and limited financial disclosure as key cautions.

Is FSPM stock a good long-term investment?

Given FusionPharm's small scale, negative EPS of **-0.147**, and thin trading, FSPM stock presents high risk for long-term investors. Consider diversification and strict risk limits before allocating capital.

What price target does Meyka AI forecast for FSPM stock?

Meyka AI's model projects a 1-year target of **$0.00051**, a 3-year target of **$0.00074**, and a 5-year level near **$0.00086**. These are model outputs, not guarantees.

US Stocks

FSPM (FusionPharm, Inc., PNK) rises 9,900% Jan 24, 2026: monitor volume

ByHuzaifa Zahoor January 24, 2026January 24, 2026

FSPM stock moved sharply in market hours on Jan 24, 2026 after the share price jumped to $0.00010, a one-day increase of 9,900.00% from the prior close. The ticker FSPM (FusionPharm, Inc.) on the PNK exchange saw volume of 300 shares versus an average of 2,586, producing a large relative volume spike. Traders flagged the move in the Healthcare sector, where FusionPharm operates in Medical – Pharmaceuticals, and the action appears driven by low-float dynamics rather than company fundamentals. We examine the price action, metrics, technicals, and Meyka AI forecasts to frame short-term trading risks and potential upside for investors.